Post-transplant diabetes mellitus (PTDM) is the most frequent metabolic complication after liver transplantation. The role of triglyceride-rich lipoprotein cholesterol (TRL-c) in PTDM risk remains poorly defined. We characterized TRL-c in liver transplant recipients (LTRs) from the TransplantLines cohort (NCT03272841) compared to the general population (PREVEND cohort; NCT03073018) and evaluated its association with incident PTDM. We compared 367 adult LTRs and 4,837 PREVEND participants with TRL-c measurements derived from total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c), all measured by nuclear magnetic resonance spectroscopy. Incident PTDM...

BACKGROUND: Impaired memory function is a frequent yet understudied symptom in kidney transplant recipients. In part, this knowledge gap reflects the lack of scalable, sensitive, and low-burden tools for quantifying memory function in large clinical populations. The aim of this study is to evaluate a brief, remote memory assessment and to examine memory function and its clinical correlates in kidney transplant recipients compared with healthy controls. METHODS: In this cross-sectional study, we demonstrate a remote, minimally burdensome memory screener, the Seattle-Groningen Memory Assessment, which estimates a patient’s speed...

Newly diagnosed mantle cell lymphoma (MCL) is commonly treated with rituximab (R) combined with anthracycline-based chemotherapy, with or without autologous stem-cell transplantation (ASCT). While rituximab maintenance (RM) in clinical trials has been shown to prolong overall survival (OS), its impact at population level remains largely unknown. This study evaluates the effect of RM on outcome of patients with MCL. Patients aged ≥18 years diagnosed with MCL between 1989-2020 were identified using the Netherlands Cancer Registry, and categorized into periods reflecting R and RM implementation (1989-2000, 2001-2014, 2015-2020). Treatment...

BACKGROUND: Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [ 18F]fluorodeoxyglucose ([ 18F]FDG)-PET-guided treatment adaptation after one cycle of A-AVD improves activity while limiting exposure to intensive chemotherapy. METHODS: This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO...

The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum-based salvage chemotherapy at the University Medical Center Groningen. In total, 124 plasma samples were analysed using low-coverage whole-genome sequencing to detect copy number alterations (CNAs) and targeted sequencing with a 115-gene panel for single- and multi-nucleotide variants (SNVs/MNVs). The complete response rate at the end...